[
  {
    "question": "Prosopagnosia localization",
    "option_a": "Occipito-temporal",
    "option_b": "Occipito-parietal",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Prosopagnosia, or face blindness, is a neurological condition characterized by the inability to recognize faces. This deficit occurs despite preserved general visual acuity and object recognition. The condition is most commonly associated with lesions in the fusiform gyrus, located in the ventral (occipito-temporal) region of the brain. The fusiform face area (FFA) is specialized for facial recognition. Damage to this area, whether through stroke, trauma, or neurodegeneration, leads to prosopagnosia. Clinically, patients with prosopagnosia cannot recognize familiar faces, including those of family members, although they may use secondary cues such as voice or clothing to identify individuals. The deficit is specific to faces, while other aspects of visual processing remain intact. Diagnosis is based on clinical history and neuropsychological testing, often accompanied by neuroimaging (MRI) to identify lesions in the occipito-temporal region. Differential diagnoses include achromatopsia and other agnosias; however, these conditions typically have additional deficits (e.g., color perception issues or inability to recognize objects). There is no definitive cure for prosopagnosia. Management focuses on compensatory strategies such as teaching patients to recognize individuals using alternative cues (voice, clothing, gait) and cognitive rehabilitation. In cases secondary to acute events (like stroke), rehabilitation and supportive therapies are recommended. For pregnant or lactating patients, management remains supportive as the options are non-pharmacological. Option A (Occipito-temporal) is correct as it pinpoints the region (including the fusiform gyrus) that is critical for facial recognition. Option B (Occipito-parietal) is less specific and typically associated with spatial processing rather than complex visual discrimination tasks like face recognition. The blank options (C and D) are not applicable. 1. Prosopagnosia is most commonly due to damage to the fusiform face area in the occipito-temporal cortex. 2. Patients may compensate for the loss of facial recognition by relying on non-facial cues. 3. The condition can be either acquired or developmental. Recent functional MRI studies have reinforced the role of the fusiform face area in facial processing. Current research is exploring neural plasticity and the potential for rehabilitative therapies to help patients with prosopagnosia develop compensatory recognition strategies.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "What is true about popping nystagmus.",
    "option_a": "Slow downward deviation and rapid upward return of the eyes to the primary position",
    "option_b": "Rapid downward deviation and slow upward return of the eyes to the primary position",
    "option_c": "Rapid upward deviation and slow downward return of the eyes to the primary position",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Nystagmus is characterized by a slow drift (slow phase) in one direction and a rapid corrective saccade (fast phase) in the opposite direction. 'Popping nystagmus'\u2014often equated with ocular bobbing\u2014is a specific pattern seen in brain\u2010stem (especially pontine) lesions, where the eyes slowly deviate downward and then rapidly snap back to the primary position. Lesions in the pons can disrupt the central integrators and inhibitory pathways that normally stabilize gaze. The damage leads to an unopposed slow downward drift of the eyes with a sudden corrective upward saccade. Recent neurophysiologic studies and imaging correlations show that such biphasic eye movement patterns stem from an imbalance between vestibular inputs and the ocular motor control system in the brainstem. This finding is typically associated with severe brainstem pathology, such as pontine hemorrhage or infarction. Clinically, patients often present with altered levels of consciousness and other brainstem signs, making this eye movement abnormality a useful localizing sign in a critically ill patient. The diagnosis is largely clinical, supported by neuroimaging (MRI) to confirm pontine pathology. Differential diagnoses include other types of nystagmus (e.g., upbeat or downbeat nystagmus seen in midbrain or cerebellar lesions, and vestibular nystagmus of peripheral origin) which can be distinguished based on the speed and direction of the slow and fast phases. Management focuses on addressing the underlying cause (e.g., stroke, hemorrhage) with prompt stabilization in an intensive care setting. Measures include blood pressure and intracranial pressure control, and possibly neurosurgical intervention. In pregnant or lactating patients, neuroimaging protocols are adjusted to avoid ionizing radiation (using MRI when possible), and treatments are chosen to minimize fetal exposure while ensuring maternal safety. Option A correctly describes the typical pattern of popping nystagmus\u2014a slow downward deviation with rapid upward correction. Option B (the marked answer) incorrectly reverses the phases (rapid downward and slow upward), and Option C describes an entirely different pattern inconsistent with the classic description. 1. Popping nystagmus (ocular bobbing) is a key localizing sign for pontine pathology. 2. The slow phase direction reflects the underlying drift due to impaired central integration. 3. Rapid recognition can expedite neuroimaging and critical care management. Recent literature and neuro-ophthalmologic reviews underscore the importance of ocular motor patterns in localizing brainstem lesions. Updated clinical guidelines recommend prompt MRI evaluation in patients with abnormal nystagmus patterns and brainstem signs, particularly in the neurocritical setting.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Where is the location of popping nystagmus.",
    "option_a": "Pons",
    "option_b": "Midbrain",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Nystagmus is characterized by a slow drift (slow phase) in one direction and a rapid corrective saccade (fast phase) in the opposite direction. 'Popping nystagmus'\u2014often equated with ocular bobbing\u2014is a specific pattern seen in brain\u2010stem (especially pontine) lesions, where the eyes slowly deviate downward and then rapidly snap back to the primary position. Lesions in the pons can disrupt the central integrators and inhibitory pathways that normally stabilize gaze. The damage leads to an unopposed slow downward drift of the eyes with a sudden corrective upward saccade. Recent neurophysiologic studies and imaging correlations show that such biphasic eye movement patterns stem from an imbalance between vestibular inputs and the ocular motor control system in the brainstem. This finding is typically associated with severe brainstem pathology, such as pontine hemorrhage or infarction. Clinically, patients often present with altered levels of consciousness and other brainstem signs, making this eye movement abnormality a useful localizing sign in a critically ill patient. The diagnosis is largely clinical, supported by neuroimaging (MRI) to confirm pontine pathology. Differential diagnoses include other types of nystagmus (e.g., upbeat or downbeat nystagmus seen in midbrain or cerebellar lesions, and vestibular nystagmus of peripheral origin) which can be distinguished based on the speed and direction of the slow and fast phases. Management focuses on addressing the underlying cause (e.g., stroke, hemorrhage) with prompt stabilization in an intensive care setting. Measures include blood pressure and intracranial pressure control, and possibly neurosurgical intervention. In pregnant or lactating patients, neuroimaging protocols are adjusted to avoid ionizing radiation (using MRI when possible), and treatments are chosen to minimize fetal exposure while ensuring maternal safety. Option A correctly describes the typical pattern of popping nystagmus\u2014a slow downward deviation with rapid upward correction. Option B (the marked answer) incorrectly reverses the phases (rapid downward and slow upward), and Option C describes an entirely different pattern inconsistent with the classic description. 1. Popping nystagmus (ocular bobbing) is a key localizing sign for pontine pathology. 2. The slow phase direction reflects the underlying drift due to impaired central integration. 3. Rapid recognition can expedite neuroimaging and critical care management. Recent literature and neuro-ophthalmologic reviews underscore the importance of ocular motor patterns in localizing brainstem lesions. Updated clinical guidelines recommend prompt MRI evaluation in patients with abnormal nystagmus patterns and brainstem signs, particularly in the neurocritical setting.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Lady come with abnormal moving eyes with large amputated and low frequency toward the right?",
    "option_a": "Cervicomedullary junction",
    "option_b": "Cerebellopontine angle",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Nystagmus is characterized by a slow drift (slow phase) in one direction and a rapid corrective saccade (fast phase) in the opposite direction. 'Popping nystagmus'\u2014often equated with ocular bobbing\u2014is a specific pattern seen in brain\u2010stem (especially pontine) lesions, where the eyes slowly deviate downward and then rapidly snap back to the primary position. Lesions in the pons can disrupt the central integrators and inhibitory pathways that normally stabilize gaze. The damage leads to an unopposed slow downward drift of the eyes with a sudden corrective upward saccade. Recent neurophysiologic studies and imaging correlations show that such biphasic eye movement patterns stem from an imbalance between vestibular inputs and the ocular motor control system in the brainstem. This finding is typically associated with severe brainstem pathology, such as pontine hemorrhage or infarction. Clinically, patients often present with altered levels of consciousness and other brainstem signs, making this eye movement abnormality a useful localizing sign in a critically ill patient. The diagnosis is largely clinical, supported by neuroimaging (MRI) to confirm pontine pathology. Differential diagnoses include other types of nystagmus (e.g., upbeat or downbeat nystagmus seen in midbrain or cerebellar lesions, and vestibular nystagmus of peripheral origin) which can be distinguished based on the speed and direction of the slow and fast phases. Management focuses on addressing the underlying cause (e.g., stroke, hemorrhage) with prompt stabilization in an intensive care setting. Measures include blood pressure and intracranial pressure control, and possibly neurosurgical intervention. In pregnant or lactating patients, neuroimaging protocols are adjusted to avoid ionizing radiation (using MRI when possible), and treatments are chosen to minimize fetal exposure while ensuring maternal safety. Option A correctly describes the typical pattern of popping nystagmus\u2014a slow downward deviation with rapid upward correction. Option B (the marked answer) incorrectly reverses the phases (rapid downward and slow upward), and Option C describes an entirely different pattern inconsistent with the classic description. 1. Popping nystagmus (ocular bobbing) is a key localizing sign for pontine pathology. 2. The slow phase direction reflects the underlying drift due to impaired central integration. 3. Rapid recognition can expedite neuroimaging and critical care management. Recent literature and neuro-ophthalmologic reviews underscore the importance of ocular motor patterns in localizing brainstem lesions. Updated clinical guidelines recommend prompt MRI evaluation in patients with abnormal nystagmus patterns and brainstem signs, particularly in the neurocritical setting.",
    "exam_year": "2024",
    "exam_type": "Part I"
  },
  {
    "question": "Picture of autonomic dysfunction (with pupillary changes? miosis) what is the antibody:",
    "option_a": "Anti Ganglionic Acetylcholine antibody",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Autoimmune autonomic ganglionopathy is a disorder caused by antibodies directed against the nicotinic acetylcholine receptors located at autonomic ganglia. This immune-mediated disruption leads to widespread dysfunction of both sympathetic and parasympathetic systems, which can manifest with various signs including pupillary abnormalities such as miosis. The anti-ganglionic acetylcholine receptor antibodies bind to nicotinic receptors at the autonomic ganglia. This binding disrupts synaptic transmission between pre-ganglionic and post-ganglionic neurons, resulting in impaired autonomic signaling which produces symptoms like orthostatic hypotension, altered gastrointestinal motility, urinary retention, and abnormal pupillary responses. Patients with autoimmune autonomic ganglionopathy may present with a constellation of signs including orthostatic hypotension, gastrointestinal dysmotility, dry eyes/mouth, and pupillary changes (e.g., miosis). Recognition of these clinical features is crucial since they guide the clinician toward immune-mediated autonomic dysfunction, distinct from other causes of dysautonomia such as diabetic autonomic neuropathy or neurodegenerative disorders. The diagnosis is based on clinical evaluation combined with laboratory testing for anti-ganglionic acetylcholine receptor antibodies. Ancillary tests including autonomic function testing (e.g., tilt-table testing) help to differentiate autoimmune autonomic ganglionopathy from other conditions like diabetic neuropathy, multiple system atrophy, or paraneoplastic syndromes. Management involves immunotherapy aimed at reducing antibody production. First-line treatments include corticosteroids, intravenous immunoglobulin (IVIG), or plasmapheresis. Supportive care of autonomic symptoms is also important. In pregnant or lactating patients, IVIG is generally considered safe and is preferred over other immunosuppressants that might pose risks to the fetus or infant. Any use of corticosteroids or alternative immunosuppressive agents in these populations requires careful consideration of the risk-benefit ratio and close monitoring by a multidisciplinary team. Given the clinical picture of autonomic dysfunction with miosis and other dysautonomic features, and in the context of the listed option, Anti Ganglionic Acetylcholine antibody correctly identifies the underlying immunologic marker in autoimmune autonomic ganglionopathy. The other options were not provided, but based on current evidence, option A is the proper answer. Consider autoimmune etiologies in patients with unexplained, multisystem autonomic failure. Testing for anti-ganglionic acetylcholine receptors can provide the definitive clue in diagnosing autoimmune autonomic ganglionopathy. In management, always consider the safety profiles of immunomodulatory therapies, especially in young women who may be pregnant or breastfeeding. Recent research supports the role of anti-ganglionic acetylcholine receptor antibodies in the pathogenesis and diagnosis of autoimmune autonomic ganglionopathy. Guidelines emphasize early diagnosis and the use of immunomodulatory treatments, with IVIG being favored in pregnant or lactating patients due to its acceptable safety profile. Emerging studies continue to refine the optimal therapeutic approach and long-term management of these patients.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "In congenital myasthenic syndromes What is the gene defect that causes worsening of symptoms with Acetylcholinesterase inhibitors (long scenario with details about the pt. including intrinsic hand atrophy, external ophthalmoplegia and weakness further details not known):",
    "option_a": "DOK7",
    "option_b": "Rapsyn",
    "option_c": "slow channel",
    "option_d": "fast channel",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Congenital Myasthenic Syndromes (CMS) are a heterogeneous group of inherited disorders affecting neuromuscular transmission. One subtype, the slow-channel CMS, is characterized by mutations in the genes encoding subunits of the acetylcholine receptor (AChR) that lead to prolonged channel opening during synaptic transmission. In slow-channel CMS, mutations in the AChR subunits result in prolonged opening of the receptor\u2019s ion channel. This causes excessive cation entry, particularly calcium, which in turn leads to endplate myopathy and structural degeneration at the neuromuscular junction. The administration of acetylcholinesterase inhibitors (AChEI) further increases the availability of acetylcholine in the synaptic cleft, exaggerating the prolonged receptor activation and worsening the clinical symptoms. Patients typically present with fatigable weakness, often affecting the extraocular muscles (external ophthalmoplegia) and intrinsic hand muscles (leading to atrophy). A notable clinical pearl is that symptoms worsen with cholinesterase inhibitors, which differentiates slow-channel syndrome from other CMS subtypes where these inhibitors might be beneficial. The workup involves neurophysiological studies such as repetitive nerve stimulation and single-fiber electromyography. Genetic testing is critical to differentiate among CMS subtypes (e.g., DOK7, rapsyn mutations versus slow-channel and fast-channel mutations). Differentiation from autoimmune myasthenia gravis (which typically responds to AChEI) is also essential. For slow-channel CMS, the first-line management involves the use of open channel blockers such as quinidine or fluoxetine, which help reduce excessive receptor activation. Acetylcholinesterase inhibitors are contraindicated as they worsen symptoms. In cases involving pregnancy or lactation, treatment decisions must carefully balance maternal benefits and fetal risks; available agents should be evaluated for safety in these populations, and specialist consultation is advised. A: DOK7 \u2013 Typically leads to a limb-girdle pattern of weakness and shows poor or paradoxical response to AChEI but does not classically present with worsening due to cholinesterase inhibitors. B: Rapsyn \u2013 Mutations here are also associated with CMS but usually improve on AChEI therapy. C: slow channel \u2013 The correct answer; this mutation causes prolonged channel opening and symptom worsening with AChEI. D: fast channel \u2013 These mutations cause a decreased open time of the channel, presenting with different features and do not characteristically worsen with AChEI. \u2022 Slow-channel CMS is a classic example where standard treatment for myasthenic syndromes (AChEI) can be harmful. \u2022 Genetic testing is essential to determine the correct subtype of CMS and to guide management. \u2022 Treatments such as quinidine and fluoxetine are used off-label to mitigate prolonged channel opening. Recent studies have underscored the importance of genotype-specific therapy in CMS. High-throughput genetic screening has improved diagnostic accuracy, and ongoing research is exploring targeted therapies that modulate receptor kinetics. Current guidelines emphasize avoiding AChEI in slow-channel CMS to prevent iatrogenic deterioration.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Most common trochlear nerve palsy",
    "option_a": "TRAUMA",
    "option_b": "CONGENITAL",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroophthalmology",
    "explanation": "The trochlear nerve (cranial nerve IV) innervates the superior oblique muscle, which is responsible for intorsion and depression of the eye. Trochlear nerve palsy results in vertical diplopia and head tilt as a compensatory mechanism. Congenital trochlear nerve palsy is often due to developmental anomalies that cause underaction of the superior oblique muscle. Unlike acquired causes (e.g., trauma), congenital palsy can remain compensated until decompensation occurs later in life, unmasking diplopia. Patients may present with vertical diplopia, especially noticeable when reading or descending stairs, and tilt their head away from the affected side to compensate. Often, these patients have a long-standing history that is only recognized in adulthood when the compensatory mechanisms fail. The differential diagnosis includes traumatic trochlear nerve palsy, microvascular ischemic palsy (especially in older patients), and decompensated congenital palsies. The Bielschowsky head tilt test is a key clinical maneuver to help confirm the diagnosis. First-line management may involve prism correction for diplopia and observation if the symptoms are mild. In more significant cases, strabismus surgery (e.g., inferior oblique weakening or superior oblique tuck) can be considered. For pregnant or lactating patients, conservative management with prisms is preferred due to surgical risks and anesthesia considerations. A: Trauma \u2013 While trauma is a known cause of CN IV palsy, it is more common in the acquired setting rather than overall. B: Congenital \u2013 This is the correct answer as congenital trochlear nerve palsy is the most common type encountered. Options C and D are not provided or relevant. \u2022 A compensatory head tilt is commonly seen in patients with trochlear nerve palsy. \u2022 Congenital trochlear nerve palsy is frequently underdiagnosed until adult decompensation. \u2022 The Bielschowsky head tilt test is an important diagnostic tool. Recent ophthalmologic studies have highlighted that many cases of trochlear nerve palsy are congenital in origin. Advances in imaging and ocular motility assessments have improved recognition and management, with current guidelines favoring conservative management in mild cases.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Scenario of pt. With orange retinal structure or vessel (not sure):",
    "option_a": "YAWS",
    "option_b": "TB",
    "option_c": "MALARIA",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Malarial retinopathy is a well-documented ocular manifestation of severe malaria, particularly cerebral malaria. It involves particular retinal findings that assist in both diagnosis and prognostication. In severe malaria, sequestration of parasitized red blood cells within the retinal vasculature leads to microvascular obstruction, leakage, and subsequent retinal hemorrhages. This process causes discoloration of the retinal vessels, sometimes described as having an orange hue. Patients with cerebral malaria may exhibit altered consciousness along with characteristic retinal changes. The retinal examination may reveal hemorrhages, retinal whitening, and abnormal vessel discoloration (often described as orange or white), which serve as supportive evidence in a clinical context. The differential diagnosis for retinal lesions includes ocular tuberculosis (which typically produces choroidal tubercles that appear yellow-white) and infections like yaws. In the setting of a febrile illness with central nervous system involvement, a retinal exam combined with malaria blood smears or rapid diagnostic tests aids in confirming the diagnosis. The cornerstone of management is prompt and effective antimalarial therapy, typically with artemisinin-based combination therapies (ACTs). In the setting of pregnancy and lactation, treatment options such as artesunate are used with caution, following current WHO guidelines that balance maternal benefit with fetal risk (especially avoiding first trimester exposure when possible). A: YAWS \u2013 Yaws is a treponemal infection primarily affecting skin and bone, not typically associated with such retinal findings. B: TB \u2013 Ocular tuberculosis presents with choroidal tubercles which are distinct in appearance from the described orange discoloration. C: MALARIA \u2013 The correct answer; malarial retinopathy is known for its vessel discoloration and retinal changes in severe malaria. D: Not provided. \u2022 Malarial retinopathy, notably the vascular discoloration, is a key diagnostic clue in cerebral malaria. \u2022 Retinal examination can provide prognostic information in severe malaria cases. \u2022 Prompt antimalarial treatment is essential for reducing mortality and morbidity. Recent research has validated retinal findings as significant prognostic markers in cerebral malaria. Updates in malaria management emphasize rapid diagnosis via retinal examination combined with modern parasitological assays, and current WHO guidelines support the use of ACTs with specific recommendations for use during pregnancy and lactation.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Patient presented its right eye optic neuritis what will see in VEP:",
    "option_a": "Prolonged s100 in the right eye",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Visual Evoked Potentials (VEP) are electrophysiological tests that assess the functional integrity of the visual pathway from the retina to the occipital cortex. In optic neuritis, demyelination of the optic nerve slows nerve conduction. Optic neuritis is characterized by inflammation and demyelination of the optic nerve, usually associated with conditions such as multiple sclerosis. This demyelination leads to a delay in the transmission of visual signals, which is reflected as a prolonged latency (classically the P100 component) on the VEP. Patients with optic neuritis typically present with acute vision loss and pain on eye movement. The prolonged latency observed on VEP, often measured as a delay in the P100 wave, supports the diagnosis by demonstrating slowed conduction through the affected optic nerve. Differential diagnoses include ischemic optic neuropathy, compressive optic neuropathy, and hereditary optic neuropathies. VEP testing, combined with clinical history, MRI, and other ophthalmologic evaluations, helps differentiate demyelinating optic neuritis from these other causes. The acute management of typical optic neuritis involves high-dose intravenous corticosteroids (e.g., methylprednisolone) followed by an oral taper. In pregnancy or lactation, the use of high-dose steroids is considered when the benefits outweigh the risks; short courses are generally accepted with appropriate monitoring. Long-term management may involve disease-modifying therapies if there is an underlying demyelinating disease such as multiple sclerosis. A: Prolonged s100 in the right eye \u2013 Although the option mentions 's100', it is understood to refer to the prolonged P100 latency that is a hallmark of demyelinating optic neuritis. This is the correct finding on VEP in such cases. Options B, C, and D are not provided. \u2022 A delay in the P100 wave on VEP is a key diagnostic indicator of optic neuritis. \u2022 Optic neuritis is frequently an initial presentation of multiple sclerosis. \u2022 High-dose steroids are the primary treatment for acute optic neuritis episodes. Recent clinical trials and guidelines continue to support the use of high-dose intravenous corticosteroids for acute optic neuritis, and VEP remains a valuable, non-invasive tool in the diagnostic workup. Ongoing research into remyelination strategies and neuroprotective agents may further refine future management.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Which of the following is a major criteria or TS:",
    "option_a": "Facial angiofibroma",
    "option_b": "Renal angiomyolipoma",
    "option_c": "Retinal achromic patch",
    "option_d": "Cardiac rhabdomyoma",
    "option_e": "",
    "correct_answer": "A,B,D",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Tuberous sclerosis complex (TSC) is a neurocutaneous disorder characterized by the development of benign hamartomas in multiple organs including the skin, brain, heart, and kidneys. The diagnostic criteria for TSC are divided into major and minor features. Major criteria\u2014such as facial angiofibromas, cardiac rhabdomyomas, and renal angiomyolipomas\u2014play a pivotal role in establishing the diagnosis. Mutations in the TSC1 or TSC2 genes lead to dysregulation of the mTOR pathway, resulting in unregulated cell growth and hamartoma formation. This genetic defect is responsible for the multisystem involvement seen in patients with TSC. Clinically, patients may present with characteristic skin lesions (facial angiofibromas), central nervous system abnormalities (cortical tubers, subependymal nodules), and organ-specific masses such as cardiac rhabdomyomas or renal angiomyolipomas. Recognizing these major criteria is crucial for early diagnosis and management. The diagnosis of TSC is established based on clinical criteria supplemented by radiological and pathological evaluations. The differential diagnoses include other neurocutaneous disorders like neurofibromatosis. A comprehensive workup usually involves brain MRI, renal ultrasound or CT, echocardiography, and detailed dermatologic examination. Management is multidisciplinary, focusing on surveillance and symptomatic treatment. mTOR inhibitors such as everolimus are used to reduce the size of certain lesions. In addition, regular screening for CNS, renal, and dermatological involvement is recommended. In pregnancy and lactation, management requires special attention with careful drug selection and monitoring to minimize risks to the fetus or infant. Option A (Facial angiofibroma), Option B (Renal angiomyolipoma), and Option D (Cardiac rhabdomyoma) are all recognized as major criteria in TSC; Option C (Retinal achromic patch) is incorrect because the retinal lesions in TSC are typically hamartomas rather than achromic patches. 1. Facial angiofibromas are a classic dermatological hallmark of TSC. 2. Cardiac rhabdomyomas are often seen in infancy and may regress over time. 3. Regular renal imaging is crucial due to the potential morbidity from angiomyolipomas. The latest consensus criteria for TSC underline the importance of these major features in diagnosis. Additionally, recent studies have showcased the effectiveness of mTOR inhibitors in reducing lesion size and improving outcomes, prompting updates in management guidelines.",
    "exam_year": "2020",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with headache, MRI showed pic of Arnold Chiari; what\u2019s next step:",
    "option_a": "spine MRI.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Arnold-Chiari malformations are a group of hindbrain anomalies characterized by herniation of the cerebellar structures through the foramen magnum. Type I, the most common variant in adults, involves the descent of the cerebellar tonsils. In Chiari I malformation, a congenitally small posterior fossa leads to herniation of the cerebellar tonsils. This herniation can obstruct normal cerebrospinal fluid (CSF) flow and is often associated with syringomyelia\u2014a fluid\u2010filled cavity within the spinal cord. Patients typically present with headaches that may worsen with activities that increase intracranial pressure (such as Valsalva maneuvers) and may also exhibit signs of brainstem or spinal cord compression. Recognition of these symptoms necessitates evaluation of the entire neuraxis. Initial diagnosis is made with brain MRI, which reveals the cerebellar tonsillar descent. Given the strong association with syringomyelia, a spine MRI is the next essential step to assess for intramedullary syrinx formation. Differential diagnoses include other causes of headache and posterior fossa mass lesions. Management depends on symptom severity. Many patients with mild symptoms are managed conservatively with observation. If a syrinx is identified or if the patient develops significant neurological deficits, surgical decompression may be warranted. For pregnant patients, any surgical intervention is carefully timed and coordinated with obstetric management, while conservative measures remain the mainstay during gestation. Option A (spine MRI) is correct because it is imperative to evaluate the spinal cord for associated pathologies such as syringomyelia once an Arnold-Chiari malformation is identified on brain imaging. 1. Always evaluate the entire neuraxis in patients with a Chiari malformation. 2. The presence of a syrinx can significantly alter management strategies. 3. Positional headaches are a common and key clinical feature in Chiari I malformation. Recent literature emphasizes the importance of spinal imaging in the workup of Chiari I malformation. Advances in surgical techniques for decompression have improved outcomes, and updated guidelines are continually refining indications for intervention.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with headache and papilledema, the headache increased when she lies down and she had mild visual obscuration; next management:",
    "option_a": "weight loss.",
    "option_b": "optic sheath fenestration",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Idiopathic Intracranial Hypertension (IIH), also known as pseudotumor cerebri, is defined by elevated intracranial pressure in the absence of an intracranial mass or ventricular enlargement, most commonly affecting overweight women of childbearing age. The exact mechanism of IIH remains uncertain, but it is believed to involve impaired CSF absorption at the level of the arachnoid granulations. Obesity and hormonal factors play significant roles in the development of this condition, leading to increased intracranial pressure. Patients typically present with headaches, papilledema, and transient visual obscurations. The headache characteristically worsens in positions that promote increased intracranial pressure (such as lying down). Prompt recognition is critical to prevent permanent visual loss. After normal neuroimaging to exclude intracranial masses or venous sinus thrombosis, a lumbar puncture is performed to confirm elevated opening pressure. Differential diagnoses include intracranial masses, venous sinus thrombosis, and other causes of secondary intracranial hypertension. Initial treatment involves a dual approach: lifestyle modification with weight loss and pharmacologic therapy with carbonic anhydrase inhibitors (e.g., acetazolamide). For patients with significant or progressive visual loss, surgical options like optic nerve sheath fenestration or CSF shunting may be necessary. In pregnancy, weight management is not only beneficial but also safe; acetazolamide can be used if necessary, though it is considered Category C and should be administered after assessing risks versus benefits. Option A (weight loss) is correct as weight reduction is a cornerstone of IIH management; while acetazolamide is also an essential first-line medication, weight loss addresses the underlying risk factor and is the safest initial intervention particularly in mild cases. 1. IIH primarily affects overweight women, and weight reduction can substantially improve symptoms. 2. Regular ophthalmologic evaluations are critical to monitor for visual field deficits. 3. Acetazolamide is the primary pharmacological treatment, though lifestyle modification remains key. Updated guidelines continue to recommend weight loss combined with acetazolamide as first-line treatment. Recent studies are focusing on long-term outcomes of weight management and the potential role of bariatric surgery in refractory cases.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Female came with impaired adduction on the right gaze and nystagmus in the other eye, Dx?",
    "option_a": "Right INO",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Internuclear Ophthalmoplegia (INO) is an ocular motor disorder resulting from a lesion in the medial longitudinal fasciculus (MLF), essential for coordinated horizontal eye movements. A lesion affecting the MLF disrupts the neural connection between the abducens nucleus and the contralateral oculomotor nucleus. This interruption results in impaired adduction of the affected eye, while the contralateral (abducting) eye exhibits nystagmus. In young females, demyelinating diseases, particularly multiple sclerosis, are a common cause. Clinically, patients present with impaired adduction in one eye when attempting lateral gaze, coupled with nystagmus in the contralateral abducting eye. This presentation is a classic sign of INO and often prompts further evaluation for multiple sclerosis or other brainstem pathologies. The diagnosis is primarily clinical, supported by high-resolution MRI to identify the lesion in the MLF. Differentials include ocular myasthenia gravis (which typically shows fatigable weakness and may affect convergence) and other brainstem disorders. Management focuses on treating the underlying cause. In cases attributable to multiple sclerosis, disease-modifying therapies are initiated while symptomatic ocular therapies may be provided. In pregnant or lactating patients with MS, treatment choices must balance disease control with fetal and neonatal safety, often favoring agents with well-established safety profiles. Option A (Right INO) is correct as the clinical presentation\u2014impaired adduction in the right eye with nystagmus in the abducting left eye\u2014is characteristic of a right-sided internuclear ophthalmoplegia. 1. INO is a classic sign of demyelination in young women and should prompt evaluation for multiple sclerosis. 2. The affected eye (with impaired adduction) in INO identifies the side of the MLF lesion. 3. Early diagnosis and management of the underlying cause can help prevent progression of neurological deficits. Recent research supports the use of high-resolution MRI for early detection of brainstem lesions in suspected INO. Current MS treatment guidelines emphasize early initiation of disease-modifying therapies to improve long-term outcomes, with careful consideration of treatment adjustments during pregnancy and lactation.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient has left eye hypertropia and improved with head tilt to the left, where is the lesion?",
    "option_a": "Left midbrain",
    "option_b": "Right Midbrain",
    "option_c": "Left medulla",
    "option_d": "right medulla",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroophthalmology",
    "explanation": "This question centers on vertical strabismus\u2014in this case, left eye hypertropia\u2014and the compensatory effect of head tilt. In neuro-ophthalmology, changes in vertical alignment with head tilt help differentiate peripheral causes such as a fourth nerve (trochlear) palsy from central causes (skew deviation) due to brainstem lesions. In a typical fourth nerve palsy, tilting the head toward the side of the affected muscle worsens the deviation. Improvement with a head tilt, conversely, suggests a central misalignment (ocular tilt reaction) where the brainstem\u2019s interpretation of gravitational input is disturbed. A lesion in the right midbrain, particularly affecting structures such as the interstitial nucleus of Cajal or the neural integrators of the otolithic pathway, can disrupt normal graviceptive signaling. This disruption produces a skew deviation in which the eye contralateral to the lesion (here, the left eye) becomes hypertropic. The abnormal tilt is partially corrected by head positioning; in this case, tilting the head to the left helps to rebalance the disrupted vestibular input and improve the alignment of the eyes. Patients with brainstem lesions causing ocular tilt reaction may present with vertical diplopia, head tilt, and torsional misalignment. The fact that the left hypertropia improves with a left head tilt localizes the lesion to the contralateral (right) side of the midbrain. This is in contrast to a fourth nerve palsy, where the head tilt toward the affected side (which would be the left in a left trochlear nerve lesion) typically exacerbates the hypertropia. The differential diagnosis includes isolated fourth nerve palsy versus central skew deviation (an ocular tilt reaction due to a brainstem lesion). A complete neuro-ophthalmologic examination, including the Bielschowsky head tilt test, is essential. Neuroimaging with magnetic resonance imaging (MRI) of the brainstem should be pursued to evaluate for midbrain pathology (e.g., ischemic stroke, demyelinating lesions) that could account for the findings. In pregnant or lactating patients, MRI without contrast is preferred to avoid fetal exposure to gadolinium unless absolutely necessary. Management begins with a thorough clinical and neuro-ophthalmologic evaluation followed by appropriate neuroimaging. If a midbrain lesion (such as a stroke or demyelinating process) is identified, treatment is guided by the underlying etiology. In stroke management among pregnant and lactating patients, MRI is the imaging modality of choice due to the lack of ionizing radiation; contrast agents are used with caution after risk\u2013benefit assessment. Early neurorehabilitation and multidisciplinary care might be required depending on the cause. Prompt identification and treatment of the underlying pathology are key to preventing further neurological deficits. Option A (Left midbrain) is less likely because a left-sided lesion would more typically produce a contralateral (right eye) hypertropia. Options C and D (left or right medulla) are not as consistent with the ocular tilt reaction pattern described. The improvement of left hypertropia with tilting the head to the left localizes the dysfunction to central otolithic pathways in the right midbrain, making Option B the best answer. \u2022 In fourth nerve palsy, the hypertropia worsens with head tilt toward the affected side; compensation is usually achieved by tilting the head away from the lesion.  \u2022 In skew deviation caused by a brainstem lesion, the vertical misalignment can paradoxically improve with head tilt, serving as an important diagnostic clue.  \u2022 Always consider neuroimaging to rule out central causes when ocular tilt reaction is suspected, especially if accompanied by other brainstem signs.  \u2022 In managing neurologic emergencies in pregnant or lactating patients, MRI without contrast is generally preferred to minimize fetal exposure. Recent literature reinforces the utility of the Bielschowsky head tilt test in differentiating trochlear nerve palsies from central causes of vertical strabismus. Advances in high-resolution brain MRI have improved the identification of small lesions in the midbrain responsible for ocular tilt reactions. Guidelines on stroke imaging and management in special populations (pregnant and lactating women) underscore the need to tailor diagnostic strategies to minimize risk while ensuring rapid diagnosis and treatment.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient came with proptosis and decrease eye movements, he has brown pigmentations, what is the Dx of his eye condition?",
    "option_a": "benign optic glioma",
    "option_b": "malignant optic glioblastoma",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroophthalmology",
    "explanation": "This question presents a patient with proptosis, decreased ocular movements, and brown pigmentations. The brown pigmentations are suggestive of features seen in neurofibromatosis type 1 (NF1), such as Lisch nodules or caf\u00e9-au-lait spots. NF1 is classically associated with benign optic pathway gliomas, which typically present in childhood with gradual visual impairment and proptosis. Benign optic gliomas are low-grade, typically pilocytic astrocytomas. They arise from the optic pathway and are known for their slow-growing nature. In NF1, these lesions develop due to a genetic mutation affecting the NF1 gene on chromosome 17, leading to dysregulated cell growth in neural tissues, particularly within the optic nerves. The clinical presentation of proptosis and decreased eye movements is consistent with a mass effect from an intraorbital or optic nerve lesion. The description of brown pigmentations reinforces the association with NF1, as patients with NF1 often have characteristic Lisch nodules (iris hamartomas) and caf\u00e9-au-lait spots. This constellation of findings points toward a benign optic glioma rather than a malignant process. Diagnosing an optic glioma involves a comprehensive clinical assessment for signs of NF1 (e.g., Lisch nodules, caf\u00e9-au-lait spots, neurofibromas) and neuroimaging, typically magnetic resonance imaging (MRI) of the brain and orbits, to delineate the lesion. Differential diagnoses include orbital inflammatory processes, other neoplasms like rhabdomyosarcoma (in younger patients), or even lymphoma, but these are less likely given the pigmentary markers of NF1. Management of benign optic glioma generally involves careful observation, particularly if the tumor is stable and the patient\u2019s vision is preserved. In cases where the tumor is progressive or vision is threatened, treatment modalities may include chemotherapy. Radiotherapy is usually avoided in children due to long-term adverse effects and is particularly concerning during pregnancy or lactation because of potential teratogenic and developmental risks. In pregnant or lactating women who require treatment, management strategies should be coordinated with obstetric specialists to minimize risks to the fetus or infant. Option A (benign optic glioma) is the correct diagnosis given the clinical context and its established association with NF1. Option B (malignant optic glioblastoma) does not align with the typical presentation of NF1-related lesions and is inconsistent with the described features. The missing options (C and D) do not alter the fact that benign optic glioma best fits the clinical scenario. In children with NF1, the presence of caf\u00e9-au-lait spots and Lisch nodules should prompt a workup for optic pathway glioma if there are ocular symptoms such as proptosis or decreased vision. It is important to monitor these lesions with serial imaging and clinical evaluations. Recent guidelines emphasize the use of MRI for surveillance in children with NF1 to detect optic pathway gliomas early, allowing for timely intervention if visual function is compromised. The prevailing evidence supports a conservative management approach with observation in asymptomatic or minimally symptomatic cases, and prioritizes non-teratogenic treatment options during pregnancy and lactation.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with right RAPD and right homonymous hemianopia, where is the lesion?",
    "option_a": "left optic tract",
    "option_b": "left optic radiation",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroophthalmology",
    "explanation": "In the visual pathway, a homonymous hemianopia indicates a post-chiasmal lesion. A relative afferent pupillary defect (RAPD) suggests an asymmetry in the afferent limb; when found with homonymous hemianopia, it indicates that the lesion involves structures carrying retinal fibers from one eye more significantly\u2014in this case, the optic tract. A lesion in the left optic tract affects fibers from the left eye\u2019s temporal retina and the right eye\u2019s nasal retina. Loss of these fibers causes a right homonymous hemianopia. The unequal loss of afferent input can produce a relative afferent pupillary defect (RAPD), most notably in the right eye which contributes significantly through its nasal fibers. Patients with optic tract lesions may present with subtle RAPD and contralateral homonymous hemianopia. Although optic radiation lesions can also produce a homonymous hemianopia, they typically spare the pupillary light reflex. This distinction aids in localization of the lesion. Key differentials for right homonymous hemianopia include lesions in the left optic tract, lateral geniculate nucleus, optic radiation, or occipital lobe. The presence of a RAPD suggests involvement of the afferent fibers before the complete splitting of the pathways, pointing toward an optic tract lesion. Neuroimaging (preferably MRI) is essential to precisely locate and characterize the lesion. In pregnant or lactating patients, an MRI without contrast (or with judicious use of contrast agents if absolutely necessary) is preferred to minimize fetal exposure. Management depends on the underlying etiology. For vascular causes (stroke), prompt intervention according to stroke protocols is critical, while demyelinating lesions may be managed with corticosteroids. Compressive lesions might require neurosurgical evaluation. In pregnant or lactating patients, management must balance maternal benefits with fetal safety\u2014for instance, using non-contrast imaging modalities and selecting medications with established safety profiles. Option A (left optic tract) is correct because it explains both the right homonymous hemianopia and the presence of a relative afferent pupillary defect. Option B (left optic radiation) would produce a similar field defect but typically does not cause an RAPD since the afferent pathway remains intact. Options C and D are unspecified and not contributory. \u2022 Homonymous hemianopia localizes lesions to the post-chiasmal visual pathway.  \u2022 A relative afferent pupillary defect in a homonymous hemianopia suggests involvement of the optic tract rather than more posterior structures.  \u2022 Detailed neuro-ophthalmologic examination and high-resolution MRI are crucial for accurate lesion localization.  \u2022 In pregnancy and lactation, non-contrast MRI is preferred to avoid fetal exposure. Recent studies and clinical guidelines corroborate that optic tract lesions commonly present with both homonymous hemianopia and a mild RAPD. Advances in high-resolution neuroimaging have improved the ability to localize such lesions. Moreover, current recommendations emphasize careful use of diagnostic modalities in pregnant or lactating women, favoring non-ionizing modalities and judicious contrast use when necessary.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "pt with horner and left deviated uvula what else you will see:",
    "option_a": "Right ptosis",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroophthalmology",
    "explanation": "The clinical findings of Horner\u2019s syndrome combined with a deviated uvula strongly suggest a brainstem lesion, most notably a lateral medullary or Wallenberg syndrome. Horner\u2019s syndrome results from disruption of the descending sympathetic fibers, while a uvula deviating to the left indicates weakness of the right-sided palatal muscles (innervated by the vagus nerve, particularly via the nucleus ambiguus). In Wallenberg syndrome, additional involvement of the spinothalamic tract produces a characteristic contralateral loss of pain and temperature sensation. In lateral medullary syndrome, occlusion of the posterior inferior cerebellar artery (PICA) leads to infarction in the lateral medulla. This damages several structures: the descending sympathetic fibers (producing Horner\u2019s syndrome), the nucleus ambiguus (resulting in dysphagia, hoarseness, and palatal/uvula deviation), and the spinothalamic tract (resulting in contralateral loss of pain and temperature sensation). Patients with lateral medullary (Wallenberg) syndrome typically present with ipsilateral Horner\u2019s syndrome (ptosis, miosis, anhidrosis), dysphagia, hoarseness, ataxia, and a loss of pain and temperature sensation on the contralateral side of the body while the face may have ipsilateral deficits. The left deviation of the uvula in this case indicates right-sided involvement, as the intact muscles pull the uvula toward the normal side. The diagnosis is primarily clinical, based on a detailed neurological examination. Neuroimaging, particularly MRI of the brainstem, is crucial to confirm a lateral medullary infarct. Differential diagnoses include lateral pontine syndrome and other brainstem lesions. Attention to the distribution of sensory and motor deficits helps localize the lesion. Management follows acute stroke protocols, which include consideration for thrombolysis or mechanical thrombectomy if within the therapeutic window, antiplatelet therapy, blood pressure optimization, and supportive care. In patients who are pregnant or lactating, the choice of antiplatelet agents (like low-dose aspirin) and other medications must consider maternal\u2013fetal safety, often requiring a multidisciplinary approach to balance the benefits and risks. Statin therapy and secondary prevention measures are also part of current guidelines once the acute phase is managed. Option A (Right ptosis) merely reiterates a component of Horner\u2019s syndrome, which is already established in the stem. The marked answer, Option B, is assumed to represent an additional expected finding in lateral medullary syndrome\u2014namely, the loss of pain and temperature sensation on the contralateral (left) side of the body. This additional sign fits with the characteristic involvement of the spinothalamic tract in a lateral medullary lesion. Remember that in brainstem lesions, especially those affecting the vagus nerve, the uvula deviates away from the side of the lesion. In lateral medullary syndrome, ipsilateral Horner\u2019s syndrome together with contralateral loss of pain and temperature sensation are key indicators. Recognizing these signs early is critical because prompt management of stroke can improve outcomes. Recent clinical guidelines stress early identification of posterior circulation strokes with brain MRI to determine appropriate reperfusion strategies and supportive care. Evidence supports the use of antiplatelet therapy and statins in secondary stroke prevention; additionally, in pregnant and lactating patients, low-dose aspirin is generally considered safe, but risk\u2013benefit assessments must be individualized in consultation with obstetrics and neurology experts.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "Prosopagnosia localization?",
    "option_a": "Frontal lobe",
    "option_b": "Prietal lobe",
    "option_c": "corbus collosum",
    "option_d": "Occipital lobe",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Prosopagnosia is a disorder characterized by the inability to recognize faces despite intact vision. It is classically associated with damage to the fusiform face area, which is located in the inferior part of the temporal lobe. The underlying mechanism involves disruption of the neural network responsible for facial recognition. Lesions\u2014due to stroke, trauma, or even neurodegenerative processes\u2014in the fusiform gyrus (a specialized region in the ventral occipitotemporal pathway) impair the ability to process the configural and holistic features of faces. Patients with prosopagnosia typically have difficulty recognizing familiar faces, including those of family members and friends. They may rely on non-facial cues (like voice, gait, or clothing) for identification. The deficit is specific to faces, while object recognition remains relatively intact. Diagnosis is based on clinical history and neuropsychological testing. Differential diagnoses include other visual agnosias and memory disorders. Neuroimaging such as fMRI can help localize dysfunction in the fusiform gyrus and confirm the diagnosis. There is no curative treatment; management focuses on compensatory strategies and rehabilitation. Cognitive therapy, compensatory training, and occupational therapy can help the patient adapt. In pregnancy or lactation, non-pharmacologic therapies are preferred, and any rehabilitation approaches are safe. Option A (Frontal lobe) \u2013 Incorrect since this area does not house the face-specific processing center. Option B (Parietal lobe) \u2013 Incorrect; while involved in spatial processing, it is not the primary site for face recognition. Option C (Corpus callosum) \u2013 Incorrect; though disconnection syndromes can cause unusual deficits, it is not the classical localization for prosopagnosia. Option D (Occipital lobe) \u2013 Incorrect; basic visual processing occurs here, but face-specific processing is localized to the fusiform gyrus in the temporal lobe. Therefore, the marked answer (Temporal lobe, specifically the fusiform gyrus) is correct. 1. Prosopagnosia typically presents as selective impairment in recognizing faces while sparing other visual functions. 2. The fusiform face area in the inferior temporal lobe is critical for facial recognition. 3. Both acquired and congenital forms exist, with the acquired form most often seen after focal brain injuries. Recent neuroimaging studies highlight the role of the right-sided fusiform gyrus in face processing. Research continues to explore the neural connectivity and compensatory mechanisms in patients with developmental prosopagnosia, supporting the emphasis on the temporal lobe as the lesion site.",
    "exam_year": "2021",
    "exam_type": "Part II"
  },
  {
    "question": "A patient who Horner syndrome and did not respond to either hydroxyamphetamine or cocaine",
    "option_a": "Pre-ganglionic",
    "option_b": "Post-ganglionic",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuroophthalmology",
    "explanation": "Horner syndrome results from disruption of the sympathetic pathway supplying the eye, leading to a trio of symptoms: ptosis, miosis, and anhidrosis. The syndrome can result from lesions affecting any part of the sympatho-ocular pathway (central, preganglionic, or postganglionic). Pharmacologic testing with agents like hydroxyamphetamine is used to differentiate the lesion site: hydroxyamphetamine acts by releasing norepinephrine from intact postganglionic nerve endings. In patients with Horner syndrome, if the postganglionic neuron is intact (as in central or preganglionic lesions), hydroxyamphetamine will cause pupillary dilation. However, failure to dilate indicates that the postganglionic endings have been compromised, localizing the lesion to the postganglionic segment. After clinical confirmation of Horner syndrome (via cocaine testing which demonstrates a lack of dilation due to impaired norepinephrine reuptake), the hydroxyamphetamine test is used to determine whether the lesion is pre- or postganglionic. Differential diagnoses include anisocoria from Adie\u2019s pupil, third nerve palsy, or ocular trauma. Management involves identifying the underlying cause through imaging (e.g., MRI/MRA or CT) to rule out life\u2010threatening etiologies like carotid dissection. In pregnant or lactating women, imaging modalities without ionizing radiation (such as MRI without contrast) are preferred. Treatment is directed at the root cause rather than the sympathetic dysfunction itself. Option A (Preganglionic) is incorrect because in preganglionic lesions, hydroxyamphetamine would still cause a dilation due to intact postganglionic endings. Option B (Postganglionic) is correct because the failure of dilation to both cocaine and hydroxyamphetamine suggests loss of the postganglionic nerve endings. 1. Horner syndrome is identified by ptosis, miosis, and anhidrosis. 2. The hydroxyamphetamine test reveals a postganglionic lesion if the affected pupil fails to dilate. 3. Immediate evaluation is necessary to exclude critical causes like carotid dissection. Current guidelines emphasize neuroimaging in cases of suspected postganglionic Horner syndrome. Recent studies support the use of pharmacologic testing (including newer agents like apraclonidine) to improve diagnostic accuracy.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Tongue-neck syndrome or something like this, diagnosis",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "Unknown",
    "subspecialty": "Neuroophthalmology",
    "explanation": "The term 'tongue-neck syndrome' is not widely recognized as a distinct diagnostic entity. It is used descriptively to denote a constellation of symptoms involving tongue and neck discomfort. The pathophysiological mechanisms remain unclear. It may overlap with other neuralgias or cervicogenic pain syndromes. The lack of universally accepted diagnostic criteria contributes to its poorly defined nature. Clinically, patients may present with pain or discomfort that is difficult to categorize as a single well-defined neurological disorder. Features may mimic glossopharyngeal neuralgia, hypoglossal neuropathy, or cervical radiculopathy, but none of these perfectly explain the combination of tongue and neck pain. Diagnosis relies on a thorough history, comprehensive neurological examination, and imaging studies to exclude other causes. Differential diagnoses include glossopharyngeal neuralgia (characterized by swallowing-induced paroxysmal pain), hypoglossal neuropathy (manifesting as tongue weakness and atrophy), cervical radiculopathy (often with arm pain), and certain migraine variants. Management is largely symptomatic and may include pain modulators or nerve blocks used in neuralgias. In the context of pregnancy or lactation, non-pharmacologic interventions are preferred and any medication use should adhere to safety profiles recommended by current guidelines. Because none of the specific options (e.g., glossopharyngeal neuralgia, hypoglossal neuropathy, cervical radiculopathy, migraine) fully encompass the unique features of tongue-neck syndrome, the best response is to acknowledge that it is 'Unknown' or not well-defined. The marked answer 'B' does not accurately reflect this uncertainty, making it incorrect. 1. 'Tongue-neck syndrome' is a controversial and poorly defined clinical entity. 2. A broad differential diagnosis must be considered when faced with overlapping symptoms in the cranial and cervical regions. 3. Detailed history and multimodal imaging are essential to exclude other known disorders. Recent reviews have highlighted the lack of consensus on tongue-neck syndrome, emphasizing that further research is needed to delineate its pathology and establish diagnostic criteria. Current literature recommends a careful, individualized approach to management.",
    "exam_year": "2023",
    "exam_type": "Part II"
  }
]